Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis

Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):700-3. doi: 10.1161/01.atv.19.3.700.

Abstract

Single-point mutations in the gene coding for prothrombin (factor II:A20210) or factor V (factor V:A1691) are associated with an increased risk of venous thromboembolism. The use of oral contraceptives is also a strong and independent risk factor for the disease, and the interaction between factor V:A1691 and oral contraceptives greatly increases the risk. No information is available about the interaction between oral contraceptives and mutant prothrombin. We investigated 148 women with a first, objectively confirmed episode of deep vein thrombosis and 277 healthy women as controls. Fourteen patients (9.4%) were carriers of factor II:A20210, 24 (16.2%) of factor V:A1691, and 4 (2.7%) of both defects. Among controls, the prevalence was 2.5% for either factor II:A20210 or factor V:A1691, and there was no carrier of both the mutations. The relative risk of thrombosis was 6-fold for factor II:A20210 and 9-fold for factor V:A1691. The most prevalent circumstantial risk factor in patients and the only one observed in controls was oral contraceptive use, which per se conferred a 6-fold increased risk of thrombosis. The risk increased to 16.3 and 20.0 when women with factor II:A20210 or factor V:A1691 who used oral contraceptives were compared with noncarriers and nonusers. These figures indicate a multiplicative interaction between the genetic risk factors and oral contraceptives. No difference in the type of oral contraceptives was observed between patients and controls, those of third generation being the most frequently used (73% and 80%). We conclude that carriers of the prothrombin mutation who use oral contraceptives have a markedly increased risk of deep vein thrombosis, much higher than the risk conferred by either factor alone.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Contraceptives, Oral / administration & dosage*
  • Factor V / genetics*
  • Female
  • Genotype
  • Heterozygote
  • Homozygote
  • Humans
  • Middle Aged
  • Point Mutation*
  • Prothrombin / genetics*
  • Risk Factors
  • Venous Thrombosis / chemically induced
  • Venous Thrombosis / epidemiology
  • Venous Thrombosis / genetics*

Substances

  • Contraceptives, Oral
  • Factor V
  • Prothrombin